APP and early-onset autosomal dominant Alzheimer disease: Roflumilast, in an Alzheimer’s disease (AD) model using APP/PS1 double transgenic mice, showed reduced neuronal death, increased cAMP/CREB/BDNF signaling, and improved Bcl-2/Bax ratios [9].